Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Association between brain-derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder

Authors
Chang, Hun SooLee, Hwa-YoungHam, Byung-JooPark, Yong ChonHahn, Sang-WooJeong, Yoo-JungKim, BohyeLee, Min-Soo
Issue Date
12월-2012
Publisher
WILEY
Keywords
brain-derived neurotrophic factor; escitalopram; major depressive disorder; single nucleotide polymorphism; treatment response
Citation
ASIA-PACIFIC PSYCHIATRY, v.4, no.4, pp.241 - 249
Indexed
SCIE
SSCI
SCOPUS
Journal Title
ASIA-PACIFIC PSYCHIATRY
Volume
4
Number
4
Start Page
241
End Page
249
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/106709
DOI
10.1111/j.1758-5872.2012.00219.x
ISSN
1758-5864
Abstract
Introduction Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD). Methods One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders, and took escitalopram at a daily dose of 540?mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion. Results The proportions of M allele carriers were higher in responders than those in non-responders at 18 weeks (P?=?0.00001P?=?0.025). The percentile decrease of HAM-D scores was larger in M allele carriers than those in patients possessing VV genotype at 18 weeks (P?=?0.00020.002). The proportion of M allele carriers was higher in remitters than in non-remitters at 28 weeks (P?=?0.003P?=?0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results. Discussion These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE